[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360238-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360238-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","phase-12-study-of-pegenzileukin-a-pegylated-recombinant-non-alpha-il-2-with-cemiplimab-for-the-treatment-of-advanced-unresectable-or-metastatic-skin-cancers","Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers","","Phase 1/2, open-label multicenter evaluation assesses pegenzileukin, a pegylated non-alpha IL-2 variant designed to avoid IL-2Rα engagement while retaining IL-2Rβγ signaling, combined with cemiplimab for advanced or metastatic melanoma and cutaneous squamous cell carcinoma. Drug administration uses two pegenzileukin dose levels plus RP2D during expansion, with primary objective response rate and secondary endpoints including DLTs, PFS, safety, and exploratory biomarkers. Among 46 patients, RP2D results show ORR of 40% and 56.3% with responder durability ≥12 months, supported by expansion of NK and CD8 T-cells without increased regulatory T cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/phase-12-study-of-pegenzileukin-a-pegylated-recombinant-non-alpha-il-2-with-cemiplimab-for-the-treatment-of-advanced-unresectable-or-metastatic-skin-cancers/360238/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/phase-12-study-of-pegenzileukin-a-pegylated-recombinant-non-alpha-il-2-with-cemiplimab-for-the-treatment-of-advanced-unresectable-or-metastatic-skin-cancers/360238.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is pegenzileukin and why is it combined with cemiplimab?","Question",{"text":63,"@type":64},"Pegenzileukin is a pegylated non-alpha recombinant IL-2 variant intended to avoid IL-2Rα-driven toxicities while preserving IL-2Rβγ activation. The study combines it with cemiplimab to evaluate immune activation and antitumor activity in advanced or metastatic skin cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients and treatment cohorts structured in the Phase 1/2 study?",{"text":68,"@type":64},"The trial evaluated melanoma (Cohort A) and cutaneous squamous cell carcinoma (Cohort B). Pegenzileukin was tested at two dose levels during escalation and an RP2D during expansion, with both drugs given every 3 weeks by intravenous infusion.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study report for response and key safety findings at the RP2D?",{"text":72,"@type":64},"At the RP2D of 16 µg/kg, ORR was 40% in Cohort A1 and 56.3% in Cohort B1, with responder duration of response ≥12 months for 75.0% and 85.7% of responders, respectively. Safety included dose-limiting toxicities in four patients, and infusion-related reactions were common, with no increase of regulatory T cells reported.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360238,1790239302,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Original research  \n Phase 1/2 study of pegenzileukin, a  \npegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers  \nCarlos Rojas,1,2 Laurent Mortier  ,3 John J Park  ,4 Luis Matamala,5 Adyb Baakili  ,6 Saleem Rao,7 Jing Xu  ,7 Laurent Andrieu  ,6 Rui Wang,7 Hong Wang,7 Tobias Paehler,8 Giovanni Abbadessa,7 Paolo A Ascierto  9,10  \nTo cite: Rojas C, Mortier L, Park JJ, et al. Phase 1/2 study of pegenzileukin, apegylated recombinant nonalpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers. Journal for ImmunoTherapy of Cancer 2026;14:e014347 . doi:10 . 1136/ jitc-2025-014347  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-014347](jitc-2025-014347)) .  \nAccepted 05 May 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Adyb Baakili;  \n[adyb.baakili@sanofi.com](adyb.baakili@sanofi.com)  \nABSTRACT  \nBackground Pegenzileukin (SAR444245), a pegylated non-alpha recombinant human interleukin (IL)-2 variant, avoids engagement of the IL-2 receptor α subunit (IL- 2Rα) chain and associated toxicities, while retaining engagement of IL-2Rβγ, for activation of effector T cell and natural killer (NK) cell. The first-in-human study of pegenzileukin with pembrolizumab showed initial efficacy and tolerable safety in advanced and metastatic solid tumors. In this study, we evaluate pegenzileukin with cemiplimab for advanced or metastatic melanoma (MM) and cutaneous squamous cell carcinoma (CSCC) .  \nMethods This phase 1/2, open-label, multicenter study evaluated drug combinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16µg/kg: Cohort A1 and B1 and 24µg/kg: Cohort A2 and B2) during dose escalation and recommended phase 2 dose (RP2D) during dose expansion, while cemiplimab was given at a dose of 350mg; both drugs were administered every 3 weeks as a 30-minute intravenous infusion. The primary endpoint was the objective response rate (ORR); secondary endpoints included dose-limiting toxicities (DLTs), progressionfree survival (PFS), safety, and exploratory biomarker endpoints. Results A total of 46 patients were enrolled. At the RP2D of pegenzileukin (16µg/kg, n=20 in Cohort A1 and n=16 in Cohort B1), the ORR was 40% in Cohort A1 and 56.3% in Cohort B1 . In Cohort A1, one patient achieved a complete response, and seven achieved a partial response (PR) . In Cohort B1, nine patients achieved a PR. At the RP2D, 75.0% and 85.7% responders, respectively, in Cohort A1 and Cohort B1 had a duration of response of ≥12 months. The PFS rate at 6 months was 55 .0% in Cohort A1 and 70.7% in Cohort B1 . Five DLTs occurred in four patients: Cohort A had one case of ≥3 Grade thrombocytopenia and one of Grade 2 cytokine release syndrome, while Cohort B had one case of ≥3 Grade alanine transaminase/aspartate transaminase increases and one infusion-related reaction (IRR) . Grade 1 or 2 IRRs were the most common adverse events. Treatment led to robust expansion of NK and CD8 T-cells, without an increase of regulatory T cells.  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Melanoma and cutaneous squamous cell carcinoma (CSCC) are common skin cancers, associated with high mortality rates once the cancer progresses to advanced and metastatic stages.\u003Cbr>⇒ Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) have significantly improved the treatment of melanoma and CSCC, but a substantial proportion of patients do not respond to PD-1 inhibitors.\u003Cbr>⇒ Aldesleukin, a recombinant human interleukin (IL)-2 approved for metastatic melanoma, acts by expanding e","cbCailf5FdTotmRz","https://ap.wps.com/l/cbCailf5FdTotmRz","pdf",1469772,12,"English","# Abstract\n# Methods\n# Results\n## Objective response and durability\n## Safety and dose-limiting toxicities\n# Introduction\n# Known and added value","[{\"question\":\"What is pegenzileukin and why is it combined with cemiplimab?\",\"answer\":\"Pegenzileukin is a pegylated non-alpha recombinant IL-2 variant intended to avoid IL-2Rα-driven toxicities while preserving IL-2Rβγ activation. The study combines it with cemiplimab to evaluate immune activation and antitumor activity in advanced or metastatic skin cancers.\"},{\"question\":\"How were patients and treatment cohorts structured in the Phase 1/2 study?\",\"answer\":\"The trial evaluated melanoma (Cohort A) and cutaneous squamous cell carcinoma (Cohort B). Pegenzileukin was tested at two dose levels during escalation and an RP2D during expansion, with both drugs given every 3 weeks by intravenous infusion.\"},{\"question\":\"What did the study report for response and key safety findings at the RP2D?\",\"answer\":\"At the RP2D of 16 µg/kg, ORR was 40% in Cohort A1 and 56.3% in Cohort B1, with responder duration of response ≥12 months for 75.0% and 85.7% of responders, respectively. Safety included dose-limiting toxicities in four patients, and infusion-related reactions were common, with no increase of regulatory T cells reported.\"}]","Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers | PDF",1790139180,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20c5b59f9fc6274c3359a2af7492db91.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a5594e8f0a7a662796b60b5e4660abd.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c35a03ead36815c2a7011ed7b1776d8.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e375a0e2e822985bec84c43808a62ba.webp",980,1306]